Lower Cancer Incidence Observed in Metformin Users
Retrospective cohorts repeatedly reported reduced cancer rates in metformin-treated patients.
- 40+: Studies reviewed (Placeholder summary figure)
- 10–40%: Reported RRR range (Placeholder summary figure)
- Multiple: Cancer types flagged (Placeholder summary figure)
- Retrospective: Study design (Placeholder summary figure)
Early observational findings
Placeholder: initial registry studies noted a consistent association.
Comparing Diabetic Treatment Cohorts
Metformin users are compared to sulfonylurea or insulin users within diabetic registries.
- ~100k: Cohort size (Placeholder summary figure)
- 5–10 yrs: Follow-up (Placeholder summary figure)
- 2–3: Comparator arms (Placeholder summary figure)
- ~15: Adjustment variables (Placeholder summary figure)
Cohort construction approach
Placeholder: matched cohorts built from insurance and registry databases.
Anti-Proliferative Mechanisms Proposed
AMPK activation and mTOR pathway suppression are candidate mechanisms.
- AMPK/mTOR: Key pathway (Placeholder summary figure)
- Reduced growth: In vitro effect (Placeholder summary figure)
- Lowered: Insulin axis (Placeholder summary figure)
- Preclinical: Evidence tier (Placeholder summary figure)
Candidate biological pathways
Placeholder: laboratory studies suggest plausible tumor-suppressive pathways.
Confounding by Indication Undermines Causal Claims
Prescribing patterns may systematically favor healthier patients for metformin.
- Indication bias: Bias type (Placeholder summary figure)
- Likely present: Healthy-user effect (Placeholder summary figure)
- Possible: Immortal time bias (Placeholder summary figure)
- Residual confounding: Adjustment limits (Placeholder summary figure)
Sources of systematic bias
Placeholder: sicker patients often avoid metformin due to renal contraindications.
Placeholder: confounding by indication can fully explain observed associations.
Randomized Trials Required for Causal Proof
Prospective randomized trials are the only way to confirm a true drug effect.
- Few: Ongoing RCTs (Placeholder summary figure)
- Thousands: Trial size needed (Placeholder summary figure)
- Inconclusive: Current status (Placeholder summary figure)
- High: Priority (Placeholder summary figure)
Path to definitive evidence
Placeholder: large randomized trials remain the necessary next step.